Vanda Pharmaceuticals (NASDAQ:VNDA) Lowered to Hold at StockNews.com

StockNews.com downgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a buy rating to a hold rating in a research report sent to investors on Monday morning.

Separately, TheStreet lowered Vanda Pharmaceuticals from a c- rating to a d rating in a research report on Thursday, February 8th.

Vanda Pharmaceuticals Price Performance

Shares of Vanda Pharmaceuticals stock opened at $4.80 on Monday. Vanda Pharmaceuticals has a 1 year low of $3.30 and a 1 year high of $7.00. The firm has a market cap of $276.19 million, a PE ratio of 96.02 and a beta of 0.76. The stock has a fifty day moving average price of $4.25 and a 200-day moving average price of $4.07.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.05. Vanda Pharmaceuticals had a return on equity of 0.46% and a net margin of 1.30%. The firm had revenue of $45.27 million during the quarter, compared to analyst estimates of $37.00 million. As a group, equities analysts anticipate that Vanda Pharmaceuticals will post -0.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its holdings in Vanda Pharmaceuticals by 352.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 5,186 shares during the last quarter. CWM LLC increased its holdings in Vanda Pharmaceuticals by 61.1% in the 3rd quarter. CWM LLC now owns 7,205 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 2,732 shares during the last quarter. Raymond James & Associates purchased a new stake in Vanda Pharmaceuticals in the 4th quarter worth about $42,000. Mackenzie Financial Corp purchased a new stake in Vanda Pharmaceuticals in the 4th quarter worth about $46,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Vanda Pharmaceuticals in the 3rd quarter worth about $52,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.